Literature DB >> 8350998

Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease.

A M Saunders1, W J Strittmatter, D Schmechel, P H George-Hyslop, M A Pericak-Vance, S H Joo, B L Rosi, J F Gusella, D R Crapper-MacLachlan, M J Alberts.   

Abstract

Apolipoprotein E, type epsilon 4 allele (APOE epsilon 4), is associated with late-onset familial Alzheimer's disease (AD). There is high avidity and specific binding of amyloid beta-peptide with the protein ApoE. To test the hypothesis that late-onset familial AD may represent the clustering of sporadic AD in families large enough to be studied, we extended the analyses of APOE alleles to several series of sporadic AD patients. APOE epsilon 4 is significantly associated with a series of probable sporadic AD patients (0.36 +/- 0.042, AD, versus 0.16 +/- 0.027, controls [allele frequency estimate +/- standard error], p = 0.00031). Spouse controls did not differ from CEPH grandparent controls from the Centre d'Etude du Polymorphisme Humain (CEPH) or from literature controls. A large combined series of autopsy-documented sporadic AD patients also demonstrated highly significant association with the APOE epsilon 4 allele (0.40 +/- 0.026, p < or = 0.00001). These data support the involvement of ApoE epsilon 4 in the pathogenesis of late-onset familial and sporadic AD. ApoE isoforms may play an important role in the metabolism of beta-peptide, and APOE epsilon 4 may operate as a susceptibility gene (risk factor) for the clinical expression of AD.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8350998     DOI: 10.1212/wnl.43.8.1467

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  875 in total

1.  Risk of dementia in parents of probands with and without the apolipoprotein E4 allele. The EVA study.

Authors:  S Danet; T Brousseau; F Richard; P Amouyel; C Berr
Journal:  J Epidemiol Community Health       Date:  1999-07       Impact factor: 3.710

2.  Genetic analysis of case/control data using estimated haplotype frequencies: application to APOE locus variation and Alzheimer's disease.

Authors:  D Fallin; A Cohen; L Essioux; I Chumakov; M Blumenfeld; D Cohen; N J Schork
Journal:  Genome Res       Date:  2001-01       Impact factor: 9.043

3.  Sandwich ELISA for the measurement of Apo-E4 levels in serum and the estimation of the allelic status of Apo-E4 isoforms.

Authors:  Y Uchida; S Ito; N Nukina
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

4.  Truncated apolipoprotein E (ApoE) causes increased intracellular calcium and may mediate ApoE neurotoxicity.

Authors:  M Tolar; J N Keller; S Chan; M P Mattson; M A Marques; K A Crutcher
Journal:  J Neurosci       Date:  1999-08-15       Impact factor: 6.167

5.  A microsphere-based assay for multiplexed single nucleotide polymorphism analysis using single base chain extension.

Authors:  J Chen; M A Iannone; M S Li; J D Taylor; P Rivers; A J Nelsen; K A Slentz-Kesler; A Roses; M P Weiner
Journal:  Genome Res       Date:  2000-04       Impact factor: 9.043

Review 6.  A genetic dichotomy model for the inheritance of Alzheimer's disease and common age-related disorders.

Authors:  R E Tanzi
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 7.  Genetic risk factors in Alzheimer's disease.

Authors:  L Tilley; K Morgan; N Kalsheker
Journal:  Mol Pathol       Date:  1998-12

8.  Rapid induction of intraneuronal neurofibrillary tangles in apolipoprotein E-deficient mice.

Authors:  X Bi; A P Yong; J Zhou; C E Ribak; G Lynch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

Review 9.  The solved and unsolved mysteries of the genetics of early-onset Alzheimer's disease.

Authors:  Ekaterina Rogaeva
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

10.  Acetylcholine receptor and behavioral deficits in mice lacking apolipoprotein E.

Authors:  Jessica A Siegel; Theodore S Benice; Peter Van Meer; Byung S Park; Jacob Raber
Journal:  Neurobiol Aging       Date:  2009-01-28       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.